DR-70 as a novel diagnostic biomarker for gastric cancer

作者：Arhan Mehmet^*; Yilmaz Hulya; Onal Ibrahim K; Kocabiyik Murat; Erdal Harun; Ibis Mehmet

来源：Turkish Journal of Gastroenterology, 2015, 26(6): 480-483.

DOI：10.5152/tjg.2015.0425

• DR-70
• fibrin degradation products
• gastric cancer
• tumor markers

Background/Aims: To assess the utility of the DR-70 immunoassay in the diagnosis of gastric cancer.
Materials and Methods: A total of 29 patients with histologically proven malignant gastric tumor and 29 healthy blood donors were enrolled in this study. DR-70 immunoassay was performed using an enzyme-linked immunosorbent assay kit to quantify the serum levels of fibrin degradation products.
Results: The DR-70 values in patients with gastric cancer significantly differed from the values in controls (p<0.0001). Receiver operating characteristic curve analysis revealed >= 1.45 mu g/mL as the best cut-off value to distinguish between patients with gastric cancer and healthy controls. The area under the receiver operating characteristic curve was 0.871. Using >= 1.45 mu g/mL as the cut-off value, the DR-70 immunoassay showed a good clinical performance with a sensitivity of 82.8% and a specificity of 79.3%. The positive predictive value was 80.0%, and the negative predictive value was 82.1%.
Conclusion: The DR-70 immunoassay reliably differs between gastric cancer and healthy controls, promising to become a useful cancer detection tool in clinical practice.

• 出版日期2015-11